- Home
- AUR vs EXEL Comparison
AUR vs EXEL Comparison
Compare AUR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUR
- EXEL
- Stock Information
- Founded
- AUR 2017
- EXEL 1994
- Country
- AUR United States
- EXEL United States
- Employees
- AUR N/A
- EXEL N/A
- Industry
- AUR EDP Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUR Technology
- EXEL Health Care
- Exchange
- AUR Nasdaq
- EXEL Nasdaq
- Market Cap
- AUR 9.9B
- EXEL 11.1B
- IPO Year
- AUR N/A
- EXEL 2000
- Fundamental
- Price
- AUR $4.09
- EXEL $42.09
- Analyst Decision
- AUR Buy
- EXEL Buy
- Analyst Count
- AUR 9
- EXEL 24
- Target Price
- AUR $10.44
- EXEL $44.73
- AVG Volume (30 Days)
- AUR 19.4M
- EXEL 3.3M
- Earning Date
- AUR 10-28-2025
- EXEL 11-04-2025
- Dividend Yield
- AUR N/A
- EXEL N/A
- EPS Growth
- AUR N/A
- EXEL 53.55
- EPS
- AUR N/A
- EXEL 2.38
- Revenue
- AUR $2,000,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- AUR N/A
- EXEL $9.14
- Revenue Next Year
- AUR $939.88
- EXEL $12.51
- P/E Ratio
- AUR N/A
- EXEL $17.53
- Revenue Growth
- AUR N/A
- EXEL 9.93
- 52 Week Low
- AUR $3.99
- EXEL $31.90
- 52 Week High
- AUR $10.77
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- AUR 27.69
- EXEL 59.10
- Support Level
- AUR $4.04
- EXEL $39.83
- Resistance Level
- AUR $4.38
- EXEL $43.72
- Average True Range (ATR)
- AUR 0.26
- EXEL 1.44
- MACD
- AUR -0.06
- EXEL 0.40
- Stochastic Oscillator
- AUR 6.99
- EXEL 77.85
About AUR Aurora Innovation Inc.
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.